Alpha 2.0
Login Register
» Authors » Federica Zoratto

Federica Zoratto

Explore the profile of Federica Zoratto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 66
Citations 1483
Followers 0
Related Specialties
Oncology
Pharmacology
Allergy & Immunology
Top 10 Co-Authors
Alessio Cortellini
Michele De Tursi
Corrado Ficorella
Rossana Berardi
Raffaele Giusti
Giampiero Porzio
Marco Filetti
Alessandro Parisi
Daniele Santini
Rita Chiari
Published In
Eur J Cancer
J Immunother Cancer
Front Oncol
Onco Targets Ther
Tumori
Affiliations
Soon will be listed here.
Recent Articles
1.
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, et al.
J Immunother Cancer . 2025 Feb; 13(2). PMID: 39904562
Background: Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its...
2.
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort
Lucchetti J, Angotti L, Parisi A, Basso M, Polito M, Zoratto F, et al.
Clin Colorectal Cancer . 2025 Jan; PMID: 39856001
Background: Both aflibercept and bevacizumab-based regimens are available II-line treatment options for patients with metastatic colorectal cancer (mCRC). However, no head-to-head trials established the optimal anti-angiogenic strategy for this setting....
3.
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
Signorelli C, Calegari M, Anghelone A, Passardi A, Frassineti G, Bittoni A, et al.
Curr Oncol . 2024 Dec; 31(12):7793-7808. PMID: 39727697
Background: There is ongoing discussion around the optimal course of treatment for metastatic colorectal cancer (mCRC) following the second line. Trifluridine/tipiracil (T) and regorafenib (R) have been the mainstay of...
4.
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic
Parisi A, Giampieri R, Villani S, Magnarini A, Gelsomino F, Traisci D, et al.
Oncologist . 2024 Nov; PMID: 39591103
Background: As an extended analysis of the COVID-DELAY study, we aimed to assess the impact of the COVID-19 pandemic on diagnosis, staging, and survival outcomes among patients with colorectal cancer...
5.
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
Basso M, Signorelli C, Calegari M, Lucchetti J, Zurlo I, DellAquila E, et al.
Target Oncol . 2024 Apr; 19(3):371-382. PMID: 38613732
Background: There are few molecular markers driving treatment selection in later lines of treatment for advanced colorectal cancer patients. The vast majority of patients who progress after first- and second-line...
6.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, et al.
Eur J Cancer . 2024 Mar; 202:114006. PMID: 38489861
Purpose: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced...
7.
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis
Signorelli C, Chilelli M, Giannarelli D, Basso M, Calegari M, Anghelone A, et al.
Cancers (Basel) . 2023 Dec; 15(24). PMID: 38136304
: Patients with refractory metastatic colorectal cancer (mCRC) rarely receive third-line or further treatment. In this context, regorafenib (R) and trifluridine/tipiracil (T) are two important novel therapeutic choices with statistically...
8.
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
Signorelli C, Calegari M, Basso M, Anghelone A, Lucchetti J, Minelli A, et al.
Curr Oncol . 2023 Jun; 30(6):5456-5469. PMID: 37366896
Background: Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new...
9.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from , a multicentric, observational study
Di Lisa F, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al.
Front Oncol . 2023 Jun; 13:1152123. PMID: 37260975
Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine,...
10.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Cortellini A, DAlessio A, Cleary S, Buti S, Bersanelli M, Bordi P, et al.
Clin Cancer Res . 2023 May; 29(14):2714-2724. PMID: 37125965
Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large...